Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

VSTM – Verastem, Inc.

Float Short %

28.21

Margin Of Safety %

Put/Call OI Ratio

0.44

EPS Next Q Diff

0.81

EPS Last/This Y

0.94

EPS This/Next Y

1.06

Price

9.61

Target Price

16

Analyst Recom

1

Performance Q

-2.14

Relative Volume

0.72

Beta

0.41

Ticker: VSTM



18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-17VSTM9.150.500.2923705
2025-11-18VSTM9.270.500.7323619
2025-11-19VSTM9.270.510.0423745
2025-11-20VSTM9.820.510.0423737
2025-11-21VSTM9.980.510.2223803
2025-11-24VSTM9.850.292.2519508
2025-11-25VSTM10.240.322.2120153
2025-11-26VSTM10.630.341.5520513
2025-12-01VSTM10.340.393.6221505
2025-12-02VSTM9.770.411.2421865
2025-12-03VSTM10.050.424.4722105
2025-12-04VSTM10.60.440.0722360
2025-12-05VSTM10.380.432.2022432
2025-12-08VSTM10.260.431.1222436
2025-12-09VSTM10.10.440.6822522
2025-12-10VSTM9.990.448.4222565
2025-12-11VSTM9.430.440.2422526
2025-12-12VSTM9.610.440.2822747
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1



18 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-17VSTM9.1530.0- -2.73
2025-11-18VSTM9.2630.0- -2.73
2025-11-19VSTM9.2730.0- -2.73
2025-11-20VSTM9.8230.0- -2.73
2025-11-21VSTM9.9920.0- -2.73
2025-11-24VSTM9.8520.0- -2.73
2025-11-25VSTM10.2520.0- -2.73
2025-11-26VSTM10.6320.0- -2.73
2025-12-01VSTM10.3320.0- -2.73
2025-12-02VSTM9.7820.0- -2.73
2025-12-03VSTM10.0620.0- -2.73
2025-12-04VSTM10.6020.0- -2.73
2025-12-05VSTM10.3620.0- -2.73
2025-12-08VSTM10.2520.0- -2.73
2025-12-09VSTM10.1220.0- -2.73
2025-12-10VSTM9.9820.0- -2.73
2025-12-11VSTM9.4420.0- -2.73
2025-12-12VSTM9.6120.0- -2.73
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
18 items Current Page1 of 1



18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-17VSTM-1.5419.4029.42
2025-11-18VSTM-1.5419.4029.42
2025-11-19VSTM-1.5419.4029.42
2025-11-20VSTM-1.5419.4029.42
2025-11-21VSTM-0.5419.4029.42
2025-11-24VSTM-0.54-2.3130.52
2025-11-25VSTM-0.57-2.3130.52
2025-11-26VSTM-0.57-2.3133.13
2025-12-01VSTM-0.632.7629.37
2025-12-02VSTM-0.632.7629.37
2025-12-03VSTM-0.632.7629.37
2025-12-04VSTM-0.632.7629.37
2025-12-05VSTM-0.692.7629.37
2025-12-08VSTM-0.692.7429.36
2025-12-09VSTM-0.752.7429.36
2025-12-10VSTM-0.752.7428.22
2025-12-11VSTM-0.752.7428.21
2025-12-12VSTM-0.752.7428.21
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="VSTM" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS​

-1.35

Avg. EPS Est. Current Quarter

-0.48

Avg. EPS Est. Next Quarter

-0.54

Insider Transactions

-0.75

Institutional Transactions

2.74

Beta

0.41

Average Sales Estimate Current Quarter

16

Average Sales Estimate Next Quarter

16

Fair Value

Quality Score

4

Growth Score

45

Sentiment Score

14

Actual DrawDown %

83.8

Max Drawdown 5-Year %

-96.2

Target Price

16

P/E

Forward P/E

PEG

P/S

54.1

P/B

P/Free Cash Flow

EPS

-4.26

Average EPS Est. Cur. Y​

-2.73

EPS Next Y. (Est.)

-1.67

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1802.12

Relative Volume

0.72

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.29

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”VSTM” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VSTM” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VSTM” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VSTM” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VSTM” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VSTM” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VSTM” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Verastem, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 78
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
stock quote shares VSTM – Verastem, Inc. Stock Price stock today
news today VSTM – Verastem, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VSTM – Verastem, Inc. yahoo finance google finance
stock history VSTM – Verastem, Inc. invest stock market
stock prices VSTM premarket after hours
ticker VSTM fair value insiders trading